Core Insights - Lexaria Bioscience Corp. has entered into a Material Transfer Agreement (MTA) with a pharmaceutical company to evaluate its DehydraTECH technology in pre-clinical studies [1][2] - Initial pre-clinical studies have been completed, focusing on pharmacokinetics in animals, but results will not be disclosed [2] - Lexaria is preparing for strategic discussions with the pharmaceutical company's clinical development team regarding potential human clinical studies [3] Company Overview - Lexaria's DehydraTECH is a patented drug delivery platform that enhances the absorption of various drugs through oral delivery, aiming to improve bio-absorption and reduce side effects [4] - The company holds a strong intellectual property portfolio with 48 patents granted and additional patents pending globally [4]